CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Cumberland Pharmaceuticals Plans FDA Application for Ifetroban in Duchenne Cardiomyopathy

By Public Technologies
  • Cumberland Pharmaceuticals plans to seek FDA approval for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy, which has no specifically approved treatment.
  • The FDA granted rolling review, allowing submission of completed application sections before the full filing.
  • Reported Phase 2 FIGHT DMD results showed improved heart function with high-dose ifetroban versus controls, with no treatment-related serious adverse events.
  • Longer-term heart imaging results are being analyzed for inclusion in the application.
  • The FDA suggested a Phase 3 trial, questioned efficacy evidence and requested additional analyses, including on missing data.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610261640PR_NEWS_USPR_____CL81369) on October 26, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk